Benchmark Reiterates Buy Rating on Ligand Pharma (LGND) Following Strong Forecasts for 2025/26
Tweet Send to a Friend
Benchmark analyst Robert Wasserman reiterated a Buy rating and $220.00 price target on Ligand Pharma (NASDAQ: LGND).The analyst commented, "Ligand ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
